Review flags 4.5-fold erectile dysfunction signal with semaglutide

The wire

1. 01The Zentralblatt fur Chirurgie review reports GLP-1 agonists raise total testosterone and improve erectile function in obesity-related hypogonadism, but cites a 4.5-fold higher risk of new-onset erectile dysfunction in non-diabetic obese men on semaglutide.
2. 02Authors recommend systematic andrological and nephrological monitoring and patient education on perioperative aspiration risk from delayed gastric emptying.
3. 03This is a narrative review of a PubMed search, not new data; the authors call for prospective controlled trials with urological endpoints.

From the source

[GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects]

Zentralblatt fur Chirurgie · 2026 Sep 16 · Klotz T et al.